Patents by Inventor Sebastian Ochsenreither

Sebastian Ochsenreither has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLIN A1-TARGETED T-CELL IMMUNOTHERAPY FOR CANCER
    Publication number: 20190119326
    Abstract: Compositions and methods are provided for eliciting antigen-specific T-cell responses against human cyclin A1 (CCNA1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (AML) including leukemia stem cells (LSC) and in immunologically privileged testis cells, but not in other normal cell types. CCNA1-derived peptide epitopes that are immunogenic for T-cells including CTL are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells.
    Type: Application
    Filed: December 20, 2018
    Publication date: April 25, 2019
    Inventors: Philip Greenberg, Sebastian Ochsenreither
  • Cyclin A1-targeted T-cell immunotherapy for cancer
    Patent number: 10208086
    Abstract: Compositions and methods are provided for eliciting antigen-specific T-cell responses against human cyclin A1 (CCNA1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (AML) including leukemia stem cells (LSC) and in immunologically privileged testis cells, but not in other normal cell types. CCNA1-derived peptide epitopes that are immunogenic for T-cells including CTL are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: February 19, 2019
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Philip Greenberg, Sebastian Ochsenreither
  • CYCLIN A1-TARGETED T-CELL IMMUNOTHERAPY FOR CANCER
    Publication number: 20140322253
    Abstract: Compositions and methods are provided for eliciting antigen-specific T-cell responses against human cyclin A1 (CCNA1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (AML) including leukemia stem cells (LSC) and in immunologically privileged testis cells, but not in other normal cell types. CCNA1-derived peptide epitopes that are immunogenic for T-cells including CTL are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 30, 2014
    Inventors: Philip Greenberg, Sebastian Ochsenreither